photo: RIA Novosti / Maksim Bogodvid

The company Shionogi & Co. also announced the start of clinical vaccine trials in the current year.

The Japanese company Shionogi & Co has announced plans for the development of vaccines against coronavirus infection by expressing baculoviruses vector systems as well as clinical testing during the current year, reports ria.ru.

“The company Shionogi & Co announced the decision about the vaccine COVID-19. A subsidiary of UMN Pharma Inc. supported by the Japan Agency for medical research and development (AMED) aims to develop a vaccine based on recombinant protein using baculoviruses expressing vector system (BEVS)”, – said in a press release.

Currently, Shionogi & Co “is the coordination plans with the National Institute of infectious diseases Japan, the Ministry of health and the Agency for pharmaceuticals and medical devices with the aim to begin clinical trials of the vaccine in the next year.“

“The development of a vaccine, as the development of therapeutic drugs against COVID-19, is our top priority. We make maximum efforts to expedite the transition to preclinical and clinical trials, as well as trying to significantly expand research that would allow us to provide vaccine to 10 million people”, – stated in the document.

The world health organization (who) on 11 March announced the outbreak of a new coronavirus infection COVID-19 pandemic.